BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Additional Patients Support Clofarabine Promise; ILEX Oncology, Inc. (ILXO) Expects FDA Decision On NDA Filing By Year End


10/19/2005 5:12:23 PM

ILEX(TM) Oncology, Inc. (Nasdaq:ILXO) today announced that results were presented at the American Society of Hematology (ASH) 46th Annual Meeting and Exposition in San Diego of 19 additional patients to the pivotal Phase II clofarabine trials. These additional patient data support a 30 percent response rate, defined as complete remissions (CR), complete marrow remissions in the absence of platelet recovery (CRp) and partial remissions (PR), in children with refractory or relapsed acute lymphoblastic leukemia (ALL). In children with acute myeloid leukemia (AML) a 26 percent response rate was observed. This is the first update on clofarabine since a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) earlier this year.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES